Manufacturer eyes potent compounds

Swiss pharmaceutical group Helsinn has announced plans to create a competitive manufacturing organization focused on highly potent compounds that includes both R&D and production capabilities. Financial investments and a new organization of manufacturing sites in Ireland and Switzerland are part of the strategy. Release

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)